Percheron Therapeutics (AU:PER) has released an update.
Percheron Therapeutics has successfully completed its Share Purchase Plan, raising $1.85 million from 201 applications, allowing retail shareholders to invest on the same terms as institutions. This follows a two-tranche placement raising $13 million, positioning the company to further its initiatives and await key clinical trial data next month. The funds will support ongoing development of therapies for rare diseases, including their promising treatment for Duchenne Muscular Dystrophy.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
